Detalhe da pesquisa
1.
Immunologic predictors of vaccine responsiveness in patients with lymphoma and CLL.
J Infect Dis
; 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38437622
2.
Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy.
Blood
; 139(7): 1026-1038, 2022 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34496014
3.
Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy.
Mol Ther
; 31(3): 686-700, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36641624
4.
Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
Blood
; 136(10): 1134-1143, 2020 09 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32688395
5.
CAR-T TREK through the lymphoma universe, to boldly go where no other therapy has gone before.
Br J Haematol
; 193(3): 449-465, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33222167
6.
Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.
Haematologica
; 106(6): 1705-1713, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32414850
7.
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
N Engl J Med
; 377(26): 2545-2554, 2017 12 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29226764
8.
Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
Biol Blood Marrow Transplant
; 25(12): 2305-2321, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31446199
9.
Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy.
N Engl J Med
; 384(7): 673-674, 2021 02 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-33596362
10.
No CNS sanctuary for lymphoma from CAR T.
Blood
; 139(15): 2261-2263, 2022 04 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35420689
11.
CAR T cell viability release testing and clinical outcomes: is there a lower limit?
Blood
; 134(21): 1873-1875, 2019 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31554634
12.
Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis.
Br J Haematol
; 170(4): 504-14, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25907897
13.
Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
Cancer
; 120(2): 222-8, 2014 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24122387
14.
PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR.
Blood
; 129(8): 1039-1041, 2017 02 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-28031179
15.
Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel.
J Hematol Oncol
; 17(1): 19, 2024 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38644469
16.
Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma.
Transplant Cell Ther
; 2024 Mar 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38494076
17.
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.
Nat Med
; 30(4): 984-989, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38266761
18.
The CNS Relapse in T-Cell Lymphoma Index Predicts CNS Relapse in Patients with T- and NK-Cell Lymphomas.
Blood Adv
; 2024 May 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38739715
19.
TP53 mutations predict for poor outcomes in patients with newly diagnosed aggressive B-cell lymphomas in the current era.
Blood Adv
; 7(23): 7243-7253, 2023 12 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37851898
20.
Salvage radiotherapy for relapsed/refractory non-Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy.
Clin Transl Radiat Oncol
; 39: 100587, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36718252